Sprouts Farmers Market closes $600 million revolving credit facility
Investing.com - Truist Securities has reiterated its Buy rating on AMN Healthcare (NYSE:AMN), citing potential upside from a recovery in international travel nursing. According to InvestingPro data, AMN’s stock is currently trading significantly below its 52-week high of $70.07, suggesting potential recovery room despite recent challenges.
The firm identified international nursing as a possible source of growth for AMN Healthcare, noting that improvements in the visa process could be meaningful for the company’s performance.
Truist Securities highlighted that EB visa recipients dropped 27% year-over-year between 2022 and 2023, with 2024 likely being "another dour year for International Nursing."
The research firm estimated that international nurse revenue was nearly $200 million higher at its peak than what is likely to be generated in 2025.
Truist Securities acknowledged that while forecasting the international business remains difficult, the potential recovery in this segment could provide upside for AMN Healthcare’s overall performance.
In other recent news, AMN Healthcare reported its Q1 2025 financial results, showcasing revenue of $690 million, which exceeded the high-end guidance by 10%. The company also posted an adjusted earnings per share (EPS) of $0.45, a notable decrease from $0.97 in the previous year, although it still surpassed market expectations. In a strategic move, AMN Healthcare sold its Smart Square Scheduling technology to symplr for $75 million, with $65 million paid at closing and the remaining $10 million due by the end of 2026. This sale is expected to bolster symplr’s workforce management capabilities by integrating Smart Square’s AI-driven scheduling technology. Additionally, Moody’s has downgraded AMN Healthcare’s corporate family rating to Ba3, citing deteriorating credit metrics and a structural decline in revenues due to reduced demand in the nurse staffing industry. Despite the downgrade, AMN Healthcare is projected to maintain strong liquidity and good covenant cushions. On the governance front, Celia Huber, a Senior Partner at McKinsey & Company, has joined AMN Healthcare’s Board of Directors, bringing over 30 years of experience in healthcare strategy and performance. UBS has maintained its Neutral rating on AMN Healthcare following these developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.